Benzinga | Aug 27, 2020 07:17AM EDT

Hepion Pharmaceuticals To Present CRV431 Preclinical Data At The 2020 Digital International Liver Congress

EDISON, NJ / ACCESSWIRE / August 27, 2020 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) "Hepion", a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis ("NASH"), today announced that it will present a poster on CRV431's antifibrotic activity at the Digital International Liver Congress(tm) 2020 (EASL), taking place from August 27-29, 2020.

Dr. Joseph Kuo will present a preclinical study evaluating CRV431's ability to reduce hepatic fibrosis and fatty diet-induced body weight gain in a mouse model of NASH.

Presentation Details

CRV431 decreases diet- and chemical-driven fibrosis in livers of mice

Poster presentation number: FRI-239

Authors: Joseph Kuo1, Erika Cabrera1, Patrick Mayo2, Daren Ure2, Robert Foster2, and Philippe Gallay1

1Department of Immunology & Microbiology, The Scripps Research Institute, La Jolla, California, USA. 2Hepion Pharmaceuticals, Edison, New Jersey, USA.

Date: Friday, August 28, 2020